Extending FDA-approved cancer drug indications requires high patient numbers, study finds Post author: Post published:September 29, 2023 Post category:uncategorized Number of patient participants needed for secondary approval of a new cancer drug. You Might Also Like Exploring PRM-A as a novel glycan-targeted therapy for SARS-CoV-2 inhibition July 4, 2024 Rutgers researchers expose war’s toll on Ukraine’s hospitals May 18, 2024 New evidence-based strategy for surgeons to sustain lifelong competency April 10, 2024